Scilex Taps Related Party for Expanded $25M Credit Line

Scilex Taps Related Party for Expanded $25M Credit Line Scilex Holding Company increased an uncommitted credit line from a related party by 150%, raising the maximum principal amount from $10 million to $25 million. The June 25th agreement with Vivasor, Inc., a significant stockholder whose board is chaired by Scilex’s own Executive Chairman Dr. Henry Ji, comes as the small-cap biotech firm faces a significant cash burn. The interest rate on any borrowings is set at the Prime Rate plus 4.0%. ## Background Scilex (SCLX), like many development-stage biotechnology firms, is cash-flow negative. Its latest quarterly filing for the period ending March 31, 2024, reported cash and cash equivalents of just $4.4 million against revenues of $11.5 million and a net loss of $33.6 million. This gap between cash on hand and cash burn—the rate at which a company spends capital before generating positive cash flow—puts a premium on securing consistent funding. The stock has reflected this pressure, trading below $1.50 per share for most of the year. The financing structure itself warrants attention. An uncommitted revolving line of credit gives the borrower the option to request funds up to an agreed-upon limit, but it places no obligation on the lender—in this case, Vivasor—to actually provide the capital. This is a much weaker backstop than a committed credit line. While the company’s independent audit committee approved the transaction, the market typically applies a discount to related-party deals due to potential conflicts of interest, even when terms appear standard. ## Why it matters This expansion of insider-led financing signals that more conventional funding routes, such as a secondary stock offering or institutional debt, may be unavailable or prohibitively expensive for Scilex at its current valuation. With only $4.4 million in cash at the end of the last quarter, a $33.6 million quarterly loss implies the company requires capital to fund operations, including the commercialization of its products like ZTlido and Gloperba. Relying on an uncommitted line from an entity controlled by its own chairman concentrates risk and power. Investors who expected Scilex to secure a partnership with a larger pharmaceutical company or raise capital from unrelated institutional sources are on the wrong side of this news. The filing suggests the company is leaning on its closest backers to stay afloat. While this avoids immediate dilution from a stock sale, it makes the company highly dependent on the discretion of its chairman's affiliated entity. Short sellers may interpret the move as a sign of deepening financial distress and limited external options. ## What to watch The key observable will be the company’s actual use of this credit line. Scilex’s third-quarter 10-Q filing, due by mid-November 2024, must disclose the amount, if any, drawn down from the Vivasor facility. If Scilex reports drawing a significant portion—for example, more than $5 million—it would confirm the thesis that the company is reliant on insider funding to cover its operational cash deficit. Conversely, if the filing shows minimal use of the line alongside news of a new third-party financing or revenue-generating partnership, it would suggest the Vivasor line was merely a precautionary measure.